Feedback PLC Statement re Online Commentary (2506I)
August 07 2019 - 4:47AM
UK Regulatory
TIDMFDBK
RNS Number : 2506I
Feedback PLC
07 August 2019
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014. Upon the
publication of this announcement via Regulatory Information
Service, this inside information is now considered to be in the
public domain
Feedback plc
Statement re Online Commentary
Cambridge, 7 August 2019: Feedback plc (AIM: FDBK, "Feedback" or
the "Company"), the specialist medical imaging technology company,
notes the recent online commentary regarding a proposed equity
fundraising by the Company.
The Company confirms that, in order to develop Bleepa(TM) , the
Company's clinical messaging product, it is currently working on
completing a placing of new shares. There can be no certainty that
such fundraising will be concluded nor as to the timing or terms of
such, but a further announcement will be made as required as soon
as possible.
-Ends-
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Lindsay Melvin, CFO
Allenby Capital Limited (Nominated
Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Capital Ltd (Joint Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited +44 20 3815 8880
(Joint Broker)
Patrick Claridge / John Howes
+44 (0)20 7457 2020
Instinctif Partners feedbackplc@instinctif.com
Rozi Morris/ Deborah Bell/ Phillip
Marriage
Notes to editors
About Feedback plc
Feedback plc (AIM: FDBK) is a specialist medical imaging
technology company providing innovative software and systems,
through its fully-owned trading subsidiary, Feedback Medical
Limited. Its products advance the work of radiologists, clinicians
and medical researchers by improving workflows and giving unique
insights into diseases, particularly cancer. Feedback Medical works
with customers globally from headquarters in the internationally
renowned scientific hub of Cambridge, UK. Its proprietary
technologies are TexRAD(R) , the quantitative texture analysis tool
and Cadran, a picture archiving communication system (PACS). For
more information, see www.fbk.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STRLIFSATVIDIIA
(END) Dow Jones Newswires
August 07, 2019 05:47 ET (09:47 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2023 to Jul 2024